TY - JOUR T1 - A Blood-based Gene-expression Scoring System for Cancer Screening in Patients With Branch-duct Intraductal Papillary Mucinous Neoplasms JF - Anticancer Research JO - Anticancer Res SP - 6551 LP - 6561 DO - 10.21873/anticanres.14680 VL - 40 IS - 11 AU - REI SUZUKI AU - HIROSUMI TAMURA AU - REIKO HONMA AU - NAOKI KONNO AU - HIROKI IRIE AU - TADAYUKI TAKAGI AU - MITSURU SUGIMOTO AU - HIROYUKI ASAMA AU - YUKI SATO AU - OKUBO YOSHINORI AU - JUN NAKAMURA AU - MIKA TAKASUMI AU - TSUNETAKA KATO AU - MINAMI HASHIMOTO AU - TAKUTO HIKICHI AU - JUN-ICHI IMAI AU - SHINYA WATANABE AU - HIROMASA OHIRA Y1 - 2020/11/01 UR - http://ar.iiarjournals.org/content/40/11/6551.abstract N2 - Background: In patients with branch-duct intraductal papillary mucinous neoplasms (BD-IPMN), we aimed to develop a novel blood-based biomarker utilizing a gene-expression profile for the detection of pancreatic malignancies, such as IPMN-derived carcinoma (IPMC) or pancreatic ductal adenocarcinoma (PDAC). Patients and Methods: We enrolled 40 patients with pancreatic tumors (24 BD-IPMNs, four IPMCs and 12 PDACs) and identified the characteristic gene-expression profiles in pancreatic malignancies. Subsequently, we constructed a gene-expression scoring system for the proper diagnosis of pancreatic malignancies. The result was validated in 14 patients (five IPMNs, three IPMCs and six PDACs). Results: The scoring system utilizing the expression levels of 13 genes showed high diagnostic yield (sensitivity=94.0%, specificity=92.0% and area under the curve=0.94), which was confirmed in the validation set. Furthermore, its diagnostic yield was not reduced even in early-stage pancreatic malignancies (sensitivity=85.0%, specificity=93.0% and area under the curve=0.88). Conclusion: We developed a blood-based gene expression scoring system for cancer screening in patients with BD-IPMNs. ER -